Repatha users had fewer heart attacks than ezetimibe users in a 544,000-patient study—but the findings don't prove the drug is better

Repatha users had fewer heart attacks than ezetimibe users in a 544,000-patient study—but the findings don't prove the drug is better

An Amgen-funded observational study found Repatha users had a lower heart attack rate than ezetimibe users, but differences between patients mean the results cannot prove causation.